{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-257390","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2026-06-04T20:06:58+00:00","discovered_at":"2026-06-04T20:07:31.283213+00:00","generated_at":"2026-06-04T20:29:21.095820+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Amylyx stockholders elect directors, ratify auditor, approve say-on-pay at annual meeting","bullets":["Elected George Mclean Milne Jr., Ph.D. (76.9M for, 14.1M withheld) and Paul Fonteyne (86.3M for, 4.8M withheld) as Class II directors.","Ratified Deloitte & Touche as independent auditor for FY 2026: 102.0M for, 34.5K against, 5.6K abstain.","Approved non-binding advisory vote on named executive officer compensation: 77.5M for, 13.5M against, 21.1K abstain.","No other matters were voted on at the June 4, 2026 Annual Meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-257390","json":"https://secwatch.observer/filing/0001193125-26-257390.json","markdown":"https://secwatch.observer/filing/0001193125-26-257390.md","text":"https://secwatch.observer/filing/0001193125-26-257390.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526257390/0001193125-26-257390-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526257390/d128401d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T20:29:21.095820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}